Photodynamic therapy (PDT) is a cancer treatment approach that is not mainstream despite its inherent selectivity for tumors over healthy tissue. PDT employs a photosensitizer (PS) as a prodrug that is photoactivated to initiate localized cell death and can further elicit an antitumor immune response. The only FDA-approved PS for cancer therapy is PS is Photofrin, an organic compound. Our group is specifically interested in metal-based PSs due to their tunability and enhanced anti-cancer activity, permitting a tumor-based approach to treatment. Ruthenium- and osmium-centered PSs are particularly promising, with our own TLD1433 in Phase 2 clinical trials for the treatment of bladder cancer. This presentation will focus on the design, synthesis, and characterization of a series of metal-based PSs.

Design and development of novel metal-based photosensitizers for photodynamic therapy

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.